U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827027) titled 'Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants' on Sept. 14.
Brief Summary: This is a single-center, randomized, open, parallel-designed bioequivalence study aimed at evaluating the pharmacokinetic differences of RAY1225 injection after site and batch changes compared to before the changes.
Study Start Date: Sept. 21
Study Type: INTERVENTIONAL
Condition:
Basic Science
Intervention:
DRUG: RAY1225
Single subcutaneous injection of RAY1225 3mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Published by HT Digital Content Services with permission from Health ...